A5052083981- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Thermal Regulation in Medicine
- T-cell and B-cell Immunology
- Epigenetics and DNA Methylation
- Acute Myeloid Leukemia Research
- Liver physiology and pathology
- Genomics and Chromatin Dynamics
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Long-Term Effects of COVID-19
- Adrenal Hormones and Disorders
- Advanced Proteomics Techniques and Applications
- Pancreatic and Hepatic Oncology Research
Technical University of Munich
2016-2024
Klinikum rechts der Isar
2022
Abstract Proteome-wide measurements of protein turnover have largely ignored the impact post-translational modifications (PTMs). To address this gap, we employ stable isotope labeling and mass spectrometry to measure >120,000 peptidoforms including >33,000 phosphorylated, acetylated, ubiquitinated peptides for >9,000 native proteins. This site-resolved (SPOT) profiling discloses global site-specific differences in associated with presence or absence PTMs. While causal relationships...
Abstract Progressive respiratory failure and hyperinflammatory response is the primary cause of death in coronavirus disease 2019 (COVID-19) pandemic. Despite mounting evidence disruption hypothalamus-pituitary-adrenal axis COVID-19, relatively little known about tropism severe acute syndrome 2 (SARS-CoV-2) to adrenal glands associated changes. Here we demonstrate viral replication COVID-19 patients. Adrenal showed inflammation accompanied by inflammatory cell death. Histopathologic analysis...
Abstract Deubiquitylases (DUBs) are therapeutically amenable components of the ubiquitin machinery that stabilize substrate proteins. Their inhibition can destabilize oncoproteins may otherwise be undruggable. Here, we screened for DUB vulnerabilities in multiple myeloma, an incurable malignancy with dependency on proteasome system and identified OTUD6B as oncogene drives G1/S‐transition. LIN28B, a suppressor microRNA biogenesis, is specified bona fide cell cycle‐specific OTUD6B....
Abstract Multiple myeloma (MM) is the second most common hematological malignancy and remains incurable, thus demanding for new therapeutic targets. While pathophysiology of MM poorly understood, substantial responsiveness patients to proteasomal inhibitors (PIs) like bortezomib or carfilzomib hints towards a central role ubiquitin proteasome system (UPS). Deubiquitylases (DUBs) are therapeutically targetable components UPS, whose inhibition can destabilize oncoproteins. However, identities...
ABSTRACT Dysregulated B cell responses have been described in inflammatory-bowel disease (IBD) patients; however, the role of cells IBD pathology remained incompletely understood. We here Wiskott-Aldrich Syndrome interacting protein deficient ( Wipf1 -/- ) mice as novel mouse model spontaneous, chronic colitis modelling human IBD. Concomitant with aberrant IgG production colonic tissue mice, we identified systemic, hypo-sialylated drivers IL-1β monocytes. Pathological antibody was promoted...